SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Does anybody follow this company?

I bought it about 15 months ago on the recommendation of a
Biochemist friend who said they had their scientific act
together.

Does anybody have a feeling for their business acumen?

They seem to be adept at generating publicity but they do
not seem to have real products yet.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1169Quite impressive results, vx-661.... $79/share. Hope you have a full boat loadscaram(o)uche-4/18/2013
1168VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duratitnsaf-3/7/2013
1167Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated wittnsaf-11/10/2012
1166Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (Vtnsaf-11/10/2012
1165Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advtnsaf-9/25/2012
1164Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer tnsaf-9/4/2012
1163this looks pretty wild... pnas.orgmopgcw-7/25/2012
1162You are invited to participate in: Vertex Pharmaceuticals Incorporated Second Qtnsaf-7/19/2012
1161Vertex shares fall as investors doubt drug data By Toni Clarke and Bill Berkrtnsaf-6/29/2012
1160Data From Follow-Up Study of KALYDECO(TM) (ivacaftor) Showed Durable Improvementtnsaf-6/8/2012
1159VRTX will <i>not</i> make an HCV acquisition, according to CEO, JeffDewDiligence_on_SI16/6/2012
1158I’m a little skeptical of the valuation being ascribed to VRTX’s CF franchise ( DewDiligence_on_SI-5/7/2012
1157Vertex Pharmaceuticals (VRTX:$58.12,00$20.71,0055.36%) is up 47.5%, or $17.76, tMoneyPenny-5/7/2012
1156Vertex appears to be on a roll: HCV approval; CF approval; and good results withChris08-1/31/2012
1155FDA Approves KALYDECO(TM) (ivacaftor), the First Medicine to Treat the Underlyintnsaf-1/31/2012
1154Vertex down today due to fear of increased competition from Pharmasett drug, wheChris08-10/10/2011
1153New Drug Allows Shorter Hepatitis Therapy for Some <i>Does anyone here knzeta1961-9/15/2011
1152Vertex pill for arthritis giving encouraging results: thestreet.comChris0819/6/2011
1151Well the links seem to work now. So ignore my prior post.Chris08-6/13/2011
1150Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement for tnsaf-6/13/2011
1149What HCV page are you referring to?DewDiligence_on_SI-5/27/2011
1148Someone should tell Tuck that his page on HCV links has several links that don&#Chris08-5/27/2011
1147Musings on Incivek vs Victrelis, especially with regard to pricing: siliconinveDewDiligence_on_SI-5/23/2011
1146FDA Approves INCIVEK™ (telaprevir) for People with Hepatitis C finance.yahoo.coscaram(o)uche-5/23/2011
1145TMC435 update: siliconinvestor.comDewDiligence_on_SI-5/20/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News